Tellgen Corporation (SHE:300642)

Market Cap	3.24B -14.9%
Revenue (ttm)	392.11M +3.1%
Net Income	12.31M -59.9%
EPS	0.08 -60.0%
Shares Out	159.59M
PE Ratio	268.57
Forward PE	n/a
Dividend	0.05 (0.25%)
Ex-Dividend Date	Sep 3, 2026

Volume	18,324,805
Open	21.06
Previous Close	20.32
Day's Range	19.83 - 21.56
52-Week Range	11.04 - 30.00
Beta	0.28
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 23, 2026

About Tellgen

Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in 2003 and is based in Shanghai, China.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2003
• Employees: 683
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300642

Financial Performance

In 2025, Tellgen's revenue was 363.83 million, a decrease of -16.70% compared to the previous year's 436.78 million. Earnings were 3.59 million, a decrease of -89.61%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 29, 2026

Data Sources Report a data error